Signal mining of adverse events of proteasome inhibitors in multiple myeloma based on FAERS

Bibliographic Details
Title: Signal mining of adverse events of proteasome inhibitors in multiple myeloma based on FAERS
Authors: Yuan Peng, Yuying Zhou, Kaisen Shu, Xu Jia, Yan Zhong
Source: Frontiers in Pharmacology, Vol 15 (2024)
Publisher Information: Frontiers Media S.A., 2024.
Publication Year: 2024
Collection: LCC:Therapeutics. Pharmacology
Subject Terms: proteasome inhibitors, adverse event, signal mining, multiple myeloma, adverse event reporting system, Therapeutics. Pharmacology, RM1-950
More Details: ObjectiveTo mine and analyze adverse events (AEs) related to proteasome inhibitors in multiple myeloma based on the FDA Adverse Event Reporting System (FAERS), providing references for rational clinical medication.MethodsAE data related to multiple myeloma proteasome inhibitors were collected from the FAERS from the first quarter of 2010 to the first quarter of 2024. Signal mining of AEs was conducted using the reporting odds ratio method and Bayesian confidence propagation neural network method.ResultsA total of 8,805 reports for bortezomib, 5,264 for carfilzomib, and 8,771 for ixazomib were collected, with corresponding AE signals of 474, 279, and 287, respectively, involving 23, 21, and 22 System Organ Classes (SOCs). The report information for the three drugs tended to be consistent: more cases were reported in males than in females; the majority of patients were 65 years and over; AEs mostly occurred within 6 months of medication; the outcomes primarily consisted of hospitalization, prolonged hospital stay, and other serious adverse events; the primary reporting country was the United States. The most affected SOCs were infections and infestations, general disorders and administration site conditions, and blood and lymphatic system disorders.ConclusionThe overall distribution of AEs for the three multiple myeloma proteasome inhibitors was consistent, but there were certain differences in specific AE signal characteristics, which should be noted in clinical applications.
Document Type: article
File Description: electronic resource
Language: English
ISSN: 1663-9812
Relation: https://www.frontiersin.org/articles/10.3389/fphar.2024.1396378/full; https://doaj.org/toc/1663-9812
DOI: 10.3389/fphar.2024.1396378
Access URL: https://doaj.org/article/cf895cfe321341278426dd8ed678ccee
Accession Number: edsdoj.f895cfe321341278426dd8ed678ccee
Database: Directory of Open Access Journals
More Details
ISSN:16639812
DOI:10.3389/fphar.2024.1396378
Published in:Frontiers in Pharmacology
Language:English